Venetoclax
B-Cell Acute Lymphoblastic Leukemia, Adult
Zhejiang UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
23 Active assets in the B-Cell Acute Lymphoblastic Leukemia, Adult cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE SWOG Cancer Research Network | Phase 3 | BBB |
PEGASPARGASE National Cancer Institute (NCI) | Phase 3 | BBB |
METHOTREXATE Massachusetts General Hospital | Phase 3 | BBB |
Cyclophosphamide The First Affiliated Hospital of Soochow University | Phase 3 | BBB |
DEXAMETHASONE Mayo Clinic | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Venetoclax is also rated in:
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →